Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
IFRX
Stock Latest News
Company Announcements
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
4h ago
6K
IFRX
Premium
The Fly
InflaRx announces new izicopan in vitro findings
14h ago
IFRX
Premium
Company Announcements
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
7d ago
6K
IFRX
Premium
The Fly
InflaRx presents vilobelimab data
11d ago
IFRX
Premium
The Fly
InflaRx price target lowered to $14 from $22 at Guggenheim
21d ago
IFRX
Premium
Company Announcements
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
22d ago
6K
IFRX
Premium
The Fly
InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year
22d ago
IFRX
Premium
Pre-Earnings
IFRX Earnings this Week: How Will it Perform?
24d ago
IFRX
Premium
Company Announcements
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027
3M ago
6K
IFRX
Premium
Ratings
InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
3M ago
IFRX
Premium
The Fly
InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%
3M ago
IFRX
Premium
Company Announcements
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
3M ago
6K
IFRX
Premium
The Fly
InflaRx outlines data analyses of Phase 3 study for vilobelimab in PG
3M ago
IFRX
Premium
The Fly
InflaRx announces international nonproprietary name of “izicopan” for INF904
4M ago
IFRX
Premium
The Fly
InflaRx downgraded to Market Perform from Outperform at Leerink
4M ago
IFRX
Premium
The Fly
InflaRx downgraded to Market Perform from Outperform at Leerink
4M ago
IFRX
Premium
The Fly
Largest borrow rate increases among liquid names
4M ago
BRR
ETH
Premium
The Fly
Largest borrow rate increases among liquid names
5M ago
HPK
Premium
Ratings
Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
5M ago
IFRX
Premium
The Fly
InflaRx price target raised to $8 from $3 at Cantor Fitzgerald
5M ago
IFRX
Premium
The Fly
InflaRx price target raised to $9 from $2 at Raymond James
5M ago
IFRX
Premium
The Fly
InflaRx price target raised to $7 from $3 at Oppenheimer
5M ago
IFRX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
